Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00384553
Status:
UNKNOWN
Last Update Posted:
2006-10-06
First Post:
2006-10-05
Brief Title:
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
Sponsor:
University of Magdeburg
Organization:
University of Magdeburg
Study Overview
Official Title:
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
Status:
UNKNOWN
Status Verified Date:
2006-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study investigates toxicity and efficacy of 2 x R-DHAP followed by High dose chemotherapy R-TEC and autologous stem cell transplantation in patients with relapsed or refractory aggressive Non- Hodgkinss Lymphoma
Detailed Description:
Initial Cytoreduction is performed with DHAP- protocol using dexamethasone cytarabine and cisplatin followed by high dose chemotherapy with treosulfan etoposide and cisplatin TEC an autologous peripheral blood stem cell transplantationaPBSCT In case of only partial remission a second identical high dose chemotherapy and aPBSCT follows Patients with primary refractory disease or early relapse within 6 months should receive a allogenous stem cell transplantation For Patients with CD 20 positive B-cell lymphoma the chemotherapy regiments DHAP and TEC are combined with rituximab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None